Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C78H111N23O24 |
| Molecular Weight | 1754.8556 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)NCC(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=CPLZPRMSVOUCIQ-FHSOKALMSA-N
InChI=1S/C78H111N23O24/c1-39(91-70(117)51(14-10-30-86-78(83)84)95-71(118)50(13-8-9-29-79)94-68(115)49(80)23-26-59(81)104)64(111)89-42(4)67(114)99-56(33-45-17-21-48(103)22-18-45)75(122)101-58(35-63(109)110)76(123)96-52(24-27-60(82)105)72(119)100-54(32-44-15-19-47(102)20-16-44)69(116)87-37-61(106)93-57(34-46-36-85-38-88-46)73(120)92-40(2)65(112)90-41(3)66(113)98-55(31-43-11-6-5-7-12-43)74(121)97-53(77(124)125)25-28-62(107)108/h5-7,11-12,15-22,36,38-42,49-58,102-103H,8-10,13-14,23-35,37,79-80H2,1-4H3,(H2,81,104)(H2,82,105)(H,85,88)(H,87,116)(H,89,111)(H,90,112)(H,91,117)(H,92,120)(H,93,106)(H,94,115)(H,95,118)(H,96,123)(H,97,121)(H,98,113)(H,99,114)(H,100,119)(H,101,122)(H,107,108)(H,109,110)(H,124,125)(H4,83,84,86)/t39-,40-,41-,42-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-/m0/s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
I99M8K8AXT
Created by
admin on Sat Dec 16 11:53:10 GMT 2023 , Edited by admin on Sat Dec 16 11:53:10 GMT 2023
|
PRIMARY | |||
|
16141649
Created by
admin on Sat Dec 16 11:53:10 GMT 2023 , Edited by admin on Sat Dec 16 11:53:10 GMT 2023
|
PRIMARY | |||
|
C104663
Created by
admin on Sat Dec 16 11:53:10 GMT 2023 , Edited by admin on Sat Dec 16 11:53:10 GMT 2023
|
CONCEPT | |||
|
AT-001
Created by
admin on Sat Dec 16 11:53:10 GMT 2023 , Edited by admin on Sat Dec 16 11:53:10 GMT 2023
|
PRIMARY | The purpose of this study is to determine the safety, bioavailability, and effectiveness of an organic yeast-selenium compound in reducing brain oxidative stress. Oxidative stress in the brain has been linked to a variety oif disorders including Alzheimer's disease. Selenium is a very powerful antioxidant that could prove useful in reducing the harmful effects of oxidative stress in the brain and may help prevent diseases such as Alzheimer's. Our recent work has demonstrated that the specific type of selenium compound greatly influences it's ability to enhance brain health and prevent Alzheimer changes in mouse models of this disease. | ||
|
163362-49-0
Created by
admin on Sat Dec 16 11:53:10 GMT 2023 , Edited by admin on Sat Dec 16 11:53:10 GMT 2023
|
PRIMARY |
